Top

Journal of General Internal Medicine

Published in:

01-01-2020 | Osteoporosis | Original Research

At Odds About the Odds: Women’s Choices to Accept Osteoporosis Medications Do Not Closely Agree with Physician-Set Treatment Thresholds

Authors: Emma O. Billington, MD, A. Lynn Feasel, BN, Gregory A. Kline, MD

Published in: Journal of General Internal Medicine | Issue 1/2020

Abstract

Background

Osteoporosis guidelines recommend pharmacologic therapy based on 10-year risk of major osteoporotic fracture (MOF) and hip fracture, which may fail to account for patient-specific experiences and values.

Objective

We aimed to determine whether patient decisions to initiate osteoporosis medication agree with guideline-recommended intervention thresholds.

Design and Participants

This prospective cohort study included women aged ≥ 45 with age-associated osteoporosis who attended a group osteoporosis self-management consultation at a tertiary osteoporosis center.

Intervention

A group osteoporosis self-management consultation, during which participants received osteoporosis education and then calculated¹ their 10-year MOF and hip fracture risk using FRAX and² their predicted absolute fracture risk with therapy (assuming 40% relative reduction). Participants then made autonomous decisions regarding treatment initiation.

Main Measures

We evaluated agreement between treatment decisions and physician-set intervention thresholds (10-year MOF risk ≥ 20%, hip fracture risk ≥ 3%).

Key Results

Among 85 women (median [IQR] age 62 [58–67]), 27% accepted treatment (median [IQR] MOF risk, 15.1% [9.9–22.0]; hip fracture risk, 3.3% [1.3–5.3]), 46% declined (MOF risk, 9.5% [6.5–11.6]; hip fracture risk, 1.8% [0.6–2.3]), and 27% remained undecided (MOF risk, 14.0% [9.8–20.2]; hip fracture risk, 4.4% [1.7–4.9]). There was wide overlap in fracture risk between treatment acceptors and non-acceptors. Odds of accepting treatment were higher in women with prior fragility fracture (50% accepted; OR, 5.3; 95% CI, 1.9–15.2; p = 0.0015) and with hip fracture risk ≥ 3% (32% accepted; OR, 3.6; 95% CI, 1.4–9.2; p = 0.012), but not MOF risk ≥ 20% (47% accepted; OR, 3.0; 95% CI, 1.0–8.5; p = 0.105).

Conclusions

Informed decisions to start osteoporosis treatment are highly personal and not easily predicted using fracture risk. Guideline-recommended intervention thresholds may not permit sufficient consideration of patient preferences.

Available only for authorised users

Ubel PA. Medical Facts versus Value Judgements - Toward Preference-Sensitive Guidelines. N Engl J Med. 2015;372(26). https://doi.org/10.1056/NEJMp1504245 CrossRefPubMed

Woolf SH, Grol R, Hutchinson A, Eccles M, Grimshaw J. Clinical guidelines: potential benefits, limitations, and harms of clinical guidelines. BMJ. 1999;318(7182):527-30. https://doi.org/10.1136/bmj.318.7182.527 CrossRefPubMedPubMedCentral

Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S, et al. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ. 2010;182(17):1864-73. https://doi.org/10.1503/cmaj.100771 CrossRefPubMedPubMedCentral

Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, et al. Clinician’s Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int 2014;25(10):2359-81. https://doi.org/10.1007/s00198-014-2794-2 CrossRefPubMedPubMedCentral

Reid IR. Efficacy, effectiveness and side effects of medications used to prevent fractures. J Intern Med 2015;277(6):690-706. https://doi.org/10.1111/joim.12339 CrossRefPubMed

Leslie WD, Giangregorio LM, Yogendran M, Azimaee M, Morin S, Metge C, et al. A population-based analysis of the post-fracture care gap 1996-2008: the situation is not improving. Osteoporos Int 2012;23(5):1623-9. https://doi.org/10.1007/s00198-011-1630-1 CrossRefPubMed

Kanis JA, Borgstrom F, Compston J, Dreinhofer K, Nolte E, Jonsson L, et al. SCOPE: a scorecard for osteoporosis in Europe. Arch Osteoporos 2013;8:144. https://doi.org/10.1007/s11657-013-0144-1 CrossRefPubMedPubMedCentral

Solomon DH, Johnston SS, Boytsov NN, McMorrow D, Lane JM, Krohn KD. Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011. J Bone Miner Res 2014;29(9):1929-37. https://doi.org/10.1002/jbmr.2202 CrossRefPubMed

Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81(8):1013-22. https://doi.org/10.4065/81.8.1013 CrossRefPubMed

10.

Burden AM, Paterson JM, Solomon DH, Mamdani M, Juurlink DN, Cadarette SM. Bisphosphonate prescribing, persistence and cumulative exposure in Ontario, Canada. Osteoporos Int 2012;23(3):1075-82. https://doi.org/10.1007/s00198-011-1645-7 CrossRefPubMed

11.

Modi A, Sajjan S, Insinga R, Weaver J, Lewiecki EM, Harris ST. Frequency of discontinuation of injectable osteoporosis therapies in US patients over 2 years. Osteoporos Int 2017;28(4):1355-63. https://doi.org/10.1007/s00198-016-3886-y CrossRefPubMed

12.

Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med 2012;125(9):882-7 e1. https://doi.org/10.1016/j.amjmed.2011.12.013 CrossRefPubMed

13.

Chapman RH, Benner JS, Petrilla AA, Tierce JC, Collins SR, Battleman DS, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005;165(10):1147-52. https://doi.org/10.1001/archinte.165.10.1147 CrossRefPubMed

14.

Bungard TJ, Ghali WA, Teo KK, McAlister FA, Tsuyuki RT. Why Do Patients With Atrial Fibrillation Not Receive Warfarin? Arch Intern Med 2000;160(1):41. https://doi.org/10.1001/archinte.160.1.41 CrossRefPubMed

15.

Montgomery AA, Harding J, Fahey T. Shared decision making in hypertension: the impact of patient preferences on treatment choice. Fam Pract 2001;18(3):309-13.CrossRefPubMed

16.

McAlister FA, Connor AM, Wells G, Grover SA, Laupacis A. When should hypertension be treated? The different perspectives of Canadian family physicians and patients. Can Med Assoc J 2000;163(4):403.

17.

Steel N. Thresholds for taking antihypertensive drugs in different professional and lay groups: questionnaire survey. Bmj. 2000;320(7247):1446-7. https://doi.org/10.1136/bmj.320.7247.1446 CrossRefPubMedPubMedCentral

18.

Neuner JM, Schapira MM. The importance of physicians’ risk perception in osteoporosis treatment decision making. J Clin Densitom 2012;15(1):49-54. https://doi.org/10.1016/j.jocd.2011.07.008 CrossRefPubMed

19.

Hall SF, Edmonds SW, Lou Y, Cram P, Roblin DW, Saag KG, et al. Patient-reported reasons for nonadherence to recommended osteoporosis pharmacotherapy. J Am Pharm Assoc (2003). 2017;57(4):503-9. https://doi.org/10.1016/j.japh.2017.05.003 CrossRef

20.

Lindsay BR, Olufade T, Bauer J, Babrowicz J, Hahn R. Patient-reported barriers to osteoporosis therapy. Arch Osteoporos 2016;11(1):1-8.CrossRef

21.

Sinsky CA, Foreman-Hoffman V, Cram P. The impact of expressions of treatment efficacy and out-of-pocket expenses on patient and physician interest in osteoporosis treatment: implications for pay-for-performance programs. J Gen Intern Med 2008;23(2):164-8. https://doi.org/10.1007/s11606-007-0490-z CrossRefPubMed

22.

Kalluru R, Petrie KJ, Grey A, Nisa Z, Horne AM, Gamble GD, et al. Randomised trial assessing the impact of framing of fracture risk and osteoporosis treatment benefits in patients undergoing bone densitometry. BMJ Open 2017;7(2):e013703. https://doi.org/10.1136/bmjopen-2016-013703 CrossRefPubMedPubMedCentral

23.

Wouters H, Van Dijk L, Van Geffen EC, Geers HC, Souverein PC, Bouvy ML, et al. Do the benefits of statins outweigh their drawbacks? Assessing patients’ trade-off preferences with conjoint analysis. Int J Cardiol 2014;176(3):1220-2. https://doi.org/10.1016/j.ijcard.2014.07.219 CrossRefPubMed

24.

Winzenberg TM, Oldenburg B, Frendin S, Jones G. The design of a valid and reliable questionnaire to measure osteoporosis knowledge in women: the Osteoporosis Knowledge Assessment Tool (OKAT). BMC Musculoskelet Disord 2003;4:17. https://doi.org/10.1186/1471-2474-4-17 CrossRefPubMedPubMedCentral

25.

Khosla S, Shane E. A Crisis in the Treatment of Osteoporosis. J Bone Miner Res 2016;31(8):1485-7. https://doi.org/10.1002/jbmr.2888 CrossRefPubMed

26.

Majumdar SR, Lier DA, Hanley DA, Juby AG, Beaupre LA, Team S-P. Economic evaluation of a population-based osteoporosis intervention for outpatients with non-traumatic non-hip fractures: the “Catch a Break” 1i [type C] FLS. Osteoporos Int 2017;28(6):1965-77. https://doi.org/10.1007/s00198-017-3986-3 CrossRefPubMedPubMedCentral

27.

Danila MI, Outman RC, Rahn EJ, Mudano AS, Redden DT, Li P, et al. Evaluation of a Multimodal, Direct-to-Patient Educational Intervention Targeting Barriers to Osteoporosis Care: A Randomized Clinical Trial. J Bone Miner Res 2018;33(5):763-72. https://doi.org/10.1002/jbmr.3395 CrossRefPubMed

28.

Cram P, Wolinsky FD, Lou Y, Edmonds SW, Hall SF, Roblin DW, et al. Patient-activation and guideline-concordant pharmacological treatment after bone density testing: the PAADRN randomized controlled trial. Osteoporos Int 2016;27(12):3513-24. https://doi.org/10.1007/s00198-016-3681-9 CrossRefPubMedPubMedCentral

29.

Montori VM, Shah ND, Pencille LJ, Branda ME, Van Houten HK, Swiglo BA, et al. Use of a decision aid to improve treatment decisions in osteoporosis: the osteoporosis choice randomized trial. Am J Med 2011;124(6):549-56. https://doi.org/10.1016/j.amjmed.2011.01.013 CrossRefPubMed

30.

Fraenkel L, McGraw S. Participation in medical decision making: the patients’ perspective. Med Decis Mak 2007;27(5):533-8. https://doi.org/10.1177/0272989X07306784 CrossRef

31.

Wozniak LA, Johnson JA, McAlister FA, Beaupre LA, Bellerose D, Rowe BH, et al. Understanding fragility fracture patients’ decision-making process regarding bisphosphonate treatment. Osteoporos Int 2017;28(1):219-29. https://doi.org/10.1007/s00198-016-3693-5 CrossRefPubMed

32.

Scoville EA, Ponce de Leon Lovaton P, Shah ND, Pencille LJ, Montori VM. Why do women reject bisphosphonates for osteoporosis? A videographic study. PLoS One. 2011;6(4):e18468. https://doi.org/10.1371/journal.pone.0018468 CrossRefPubMedPubMedCentral

33.

Fenton JJ, Robbins JA, Amarnath AD, Franks P. Osteoporosis overtreatment in a regional health care system. JAMA Intern Med 2016;176(3):391-3. https://doi.org/10.1001/jamainternmed.2015.6020 CrossRefPubMed

Title: At Odds About the Odds: Women’s Choices to Accept Osteoporosis Medications Do Not Closely Agree with Physician-Set Treatment Thresholds
Authors: Emma O. Billington, MD
A. Lynn Feasel, BN
Gregory A. Kline, MD
Publication date: 01-01-2020
Publisher: Springer US
Keywords: Osteoporosis
Osteoporosis
Published in: Journal of General Internal Medicine / Issue 1/2020
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI: https://doi.org/10.1007/s11606-019-05384-x

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

At Odds About the Odds: Women’s Choices to Accept Osteoporosis Medications Do Not Closely Agree with Physician-Set Treatment Thresholds

Abstract

Background

Objective

Design and Participants

Intervention

Main Measures

Key Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Objective

Design and Participants

Intervention

Main Measures

Key Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2020

Frontline Perspectives on Physician Burnout and Strategies to Improve Well-Being: Interviews with Physicians and Health System Leaders

Satisfaction with Primary Care Providers and Health Care Services Among Patients with Chronic Pain: a Mixed-Methods Study

Effect of Mobile Device-Assisted N-of-1 Trial Participation on Analgesic Prescribing for Chronic Pain: Randomized Controlled Trial

Temporal Trends in the Loudness of Popular Music over Six Decades

Extended-Release Formulation and Medication Adherence

Mortality Among Veterans with Major Mental Illnesses Seen in Primary Care: Results of a National Study of Veteran Deaths

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page